Background In the CARD study, cabazitaxel significantly improved radiographic progression-free
survival and overall survival versus abiraterone or enzalutamide in patients with …

Background Overexpression of c-Myc is commonly seen in human ovarian cancers, and this
could be a potentially novel therapeutic target for this disease. JQ1, a selective small-…

Background Uterine sarcomas consist a heterogeneous group of mesenchymal gynecological
malignancies with unclear therapeutic recommendations and unspecific but poor …

Aim. To investigate the association of endocrine complications after ICIs immunotherapy
with progression free survival (PFS) and overall survival (OS) in a large single-center …

Recently, immunotherapy has shown promising results in solid tumors. To the best of our
knowledge, this is the first systematic review of published literature synthesizing all the …

A major challenge in cancer treatment is predicting the clinical response to anti-cancer drugs
for each individual patient. For complex diseases such as cancer, characterized by high …

Breast carcinoma is the most frequent and the second leading cause of cancer mortality in
women worldwide. Current treatment decisions are based on tumor profiling of the initial …

Introduction: The clinical outcome of HER2-positive breast cancer patients changed with the
use of anti-Her therapies, though it still remains an aggressive and fatal disease. …

While pregnancy-related malignancies are quite rare, their incidence is increasing and thus
affecting more and more women nowadays. Their management, however, with both …

Purpose The purpose of this review is to assess the impact of mechanical and oral antibiotics
bowel preparation on surgical performance and to investigate their role before gynecologic …